See All Slides - tctmd.com

Slides

Presentation TCT 2013

OPTIMIZE and ARTIC-INTERRUPTION: Perspectives on DAPT Duration after PCI

Presenter: Peter Wenaweser

October 31, 2013

Presentation TCT 2013

Absolutely Required - Now and in the Future!

Presenter: Mathew Williams

October 31, 2013

Presentation TCT 2013

Defining and Measuring Frailty: An Important Assessment Feature of High-Risk TAVR Patients

Presenter: Philip Green

October 31, 2013

Presentation TCT 2013

A Standard Cath Lab Is Adequate for All Transfemoral TAVR Cases!

Presenter: Helene Eltchaninoff

October 31, 2013

Presentation TCT 2013

Atherectomy and Drug-Coated Balloons: Device Selection, Technical Pitfalls and Available Data

Presenter: Erwin Blessing

October 31, 2013

Presentation TCT 2013

Incidence and Impact of Acquired Thrombocytopenia on Bleeding Events and Mortality after Transcatheter Aortic Valve Replacement (TAVR)

Presenter: Philippe Genereux, Susheel Kodali, Martin Leon, Philip Green, Benoit Daneault, Jean-Michel Paradis, Isaac George, Ajay Kirtane, Rebecca Hahn, Craig Smith, Mathew Williams

January 31, 2013

Presentation TCT 2013

Cost Effectiveness Of Everolimus-Eluting Stents Compared To Propensity Score Matched Bare Metal Stents In Contemporary Clinical Practice

Presenter: Robert Applegate, Matthew Sacrinty, Sanjay Gandhi, Michael Kutcher, Renato Santos, Timothy Smith, William Little

January 31, 2013

Presentation TCT 2013

Clinical Outcomes with Everolimus-Eluting Stent for the Treatment of Cardiac Allograft Vasculopathy

Presenter: Babak Azarbal, Boris Arbit, Radhakrishnan Ramaraj, David Chang, Jignesh Patel, Jon Kobashigawa

January 31, 2013

Presentation TCT 2013

Two zotarolimus-eluting stent generations: a meta-analysis of 12 randomized trials versus other limus-eluting stents and an adjusted indirect comparison.

Presenter: Salvatore Cassese, Gjin Ndrepepa, Lamin King, Tomohisa Tada, Massimiliano Fusaro, Adnan Kastrati

January 31, 2013

Presentation TCT 2013

Temporal Trends In Cost and Resource Utilization Following PCI-Associated Gastrointestinal Bleeding

Presenter: Vabhave Pal, Anupama Shivaraju, Hui Xie, Karthikeyan Thilagovindarajan, Adhir Shroff, Mladen Vidovich

January 31, 2013

Advertisement

Slides

OPTIMIZE and ARTIC-INTERRUPTION: Perspectives on DAPT Duration after PCI

Absolutely Required - Now and in the Future!

Defining and Measuring Frailty: An Important Assessment Feature of High-Risk TAVR Patients

A Standard Cath Lab Is Adequate for All Transfemoral TAVR Cases!

Atherectomy and Drug-Coated Balloons: Device Selection, Technical Pitfalls and Available Data

Incidence and Impact of Acquired Thrombocytopenia on Bleeding Events and Mortality after Transcatheter Aortic Valve Replacement (TAVR)

Cost Effectiveness Of Everolimus-Eluting Stents Compared To Propensity Score Matched Bare Metal Stents In Contemporary Clinical Practice

Clinical Outcomes with Everolimus-Eluting Stent for the Treatment of Cardiac Allograft Vasculopathy

Two zotarolimus-eluting stent generations: a meta-analysis of 12 randomized trials versus other limus-eluting stents and an adjusted indirect comparison.

Temporal Trends In Cost and Resource Utilization Following PCI-Associated Gastrointestinal Bleeding

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content